Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
Advertisement
Funxional Therapeutics Ltd has announced the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine inhibitors (BSCIs).
The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.
“We are extremely pleased with the outcome of this initial clinical study with FX125L” said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. “The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L”.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Neurotech Names Ted Danse as New President and CEO
Phidea S.r.l. - Corsico, Italy
Caprotec bioanalytics Announces the Appointment of Funakoshi as Distributor for Its Products on the Japanese Market
OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
OSI Pharmaceuticals, Inc. - Melville, USA
Paloma Pharmaceuticals, Inc. - Jamaica Plain, USA
Neurotech Pharmaceuticals, Inc. - Lincoln, RI, USA
ZERMEC Pharma AG - Laufenburg, Switzerland
Neuenhauser Automation GmbH - Naila, Germany
Oncos Therapeutics Ltd. - Helsinki, Finland